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Introduction
Multiple sclerosis (MS) is a multifocal autoimmune 
pathology of the central nervous system (CNS) affect-
ing young adults, which is characterized by acute and 
chronic inflammation, demyelination and neurode-
generation.1 Although neurodegeneration is consid-
ered to be the main substrate of irreversible disability 
in MS, this phenomenon is complex to characterize in 
vivo.2 Mechanistic approaches have provided 
evidence that sodium accumulation is involved in 
neurodegenerative processes,3,4 suggesting that meas-
urement of in vivo brain sodium accumulation may be 
a relevant marker of neurodegeneration. Sodium 
(23Na) MR imaging is a unique in vivo and non-inva-
sive technique that enables quantification of total 
sodium concentrations (TSC) in the human brain.5 
Recently, clinical 23Na-MRI studies have focused on 
MS, reporting abnormal increases of TSC in demyeli-
nated white matter (WM) T2 lesions, gadolinium-
enhancing lesions,6 normal-appearing white matter 
(NAWM) and grey matter (GM) of patients with dif-
ferent phenotypes of the disease including relapsing-
remitting multiple sclerosis (RRMS)7–9 and 
progressive multiple sclerosis (PMS) forms.10,11 
Nevertheless, as noted in a recent review, the meaning 
of observed brain sodium accumulations is unknown.12 
To refine information provided by 23Na-MRI, the use 
of new MR contrasts have been proposed such as 
Triple Quantum Filtering (TQF)13 and/or inversion 
recovery at high (3T) and ultra-high field (7T)14 in 
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order to separate sodium signals from the intra- and 
the extra-cellular compartments. Petracca et al.13 used 
TQF to demonstrate decreases in intracellular volume 
fraction and increase in intracellular sodium concen-
trations in MS patients. However, these techniques 
not only suffer from very poor sensitivity requiring 
long acquisition times and leading to poor spatial res-
olution but also did not solve the interpretation of 
23Na-MRI.
Concurrently, complementary information on physi-
ological and pathological processes can be obtained 
from metabolites detected using proton MR spectro-
scopic imaging, including (1) N-acetyl aspartate 
(NAA), which is synthesized in neuronal mitochon-
dria15 and considered to be highly linked to neuronal 
mitochondrial activity; (2) glutamate–glutamine 
(Glx), which provides a probe of neuro-astrocytic 
exchanges;16 (3) total creatine (tCr), designating the 
signals of phosphocreatine and creatine, which is pre-
sent in all cell types and considered to be an index of 
cellularity; (4) choline containing compounds (Cho), 
signals mainly detected in oligodendrocytes and 
astrocytes17 and mostly associated with membrane 
(glycerophosphorylcholine), demyelination processes 
(free choline) and inflammation (Betaine); and (5) 
myo-inositol (m-Ins), a metabolite associated with 
glial cells, microglial activation and glial scar 
processes.18
The aim of this study was to better characterize the 
metabolic counterpart of total sodium accumulations 
within the different brain compartments (T2 lesions, 
NAWM, GM) of RRMS patients in order to add spe-
cific cellular information to increase of TSC. To do 
so, we have examined the relationships between TSC 
derived from quantitative 23Na-MRI and the corre-
sponding metabolic maps of NAA, Glx, tCr, Cho and 
m-Ins assessed by volumetric proton echo planar 
spectroscopic imaging (3D 1H-EPSI) optimized to 
sample the entire brain.19
Materials and methods
Subjects
This study was approved by the local Institutional 
Review Board (Marseille Provence 2) in accordance 
with the guidelines outlined in the Declaration of 
Helsinki. All subjects gave their written consent. 
For this exploratory study and according to previous 
studies providing significant results using similar 
techniques,8,20 21 RRMS patients (mean age = 
37 ± 10.7 years, range = 23–59, 13 women, 8 men) and 
20 healthy volunteers (mean age = 33.2 ± 10.2 years, 
range = 22–60, 12 women, 8 men) matched for age and 
sex (p > 0.05) were included in this study between 
February 2014 and July 2015.
1H-MRI
MRI studies were performed on a 3-Tesla Magnetom 
Verio MR scanner (Siemens, Erlangen, Germany) using 
a 32-channel receiver head coil. The imaging protocol 
included sagittal T1-weighted FLASH, axial 3D-T1-
weighted Magnetization Prepared RApid Gradient 
Echo (MPRAGE) (TE/TR/TI = 3.44/2150/1100 ms, 
voxel size = 1 × 1 × 1 mm3, FOV = 256 mm, flip 
angle =8°, matrix = 2562, partitions = 176, acquisition 
time ≈ 5 minutes), axial T2-weighted (TE1/TE2/
TR = 11/90/8500 ms, FOV = 250 mm, flip angle = 150°, 
matrix = 2562, thickness = 3 mm, 49 slices, acquisi-
tion time ≈ 4 minutes) sequences and sagittal fluid- 
attenuated inversion recovery (FLAIR) sequence (TE/
TR/TI = 395/5000/1800 ms, voxel size = 1 × 1 × 1 mm3, 
FOV = 250 mm, flip angle = 70°; matrix = 2562, parti-
tions = 160; acquisition time ≈ 6 minutes). Patients had 
also pre- and post-gadolinium injection T1-weighted 
acquisitions to determine the presence of active lesions 
(TE/TR = 8.4/500 ms, FOV = 250 mm, flip angle = 70°, 
matrix = 2562, thickness = 3 mm, 45 slices, acquisition 
time ≈ 4 minutes).
1H-MRSI
Whole brain 3D-1H-EPSI was acquired as described 
in Lecocq and colleagues,19,20 using two axial acqui-
sitions with two different orientations, one in 
the AC-PC plane and the other in the AC-PC + 15° 
plane (TE/TR/TI = 20/1710/198 ms, nominal voxel 
size = 1 × 1 × 1 cm3, FOV = 280 × 280 × 180 mm3, flip 
angle = 73°, 50 × 50 × 18 k-space points, GeneRalized 
Autocalibrating Partial Parallel Acquisition 
(GRAPPA) factor = 2, acquisition time ≈ 17 minutes) 
and the same 32-channel receiver head coil. 
Examples of spectra obtained across the brain are 
illustrated in Figure 1.
23Na-MRI
23Na-MR imaging was performed using a double 
tuned 23Na-1H volume head coil (Rapid Biomedical, 
Rimpar, Germany). The protocol, as described in 
Zaaraoui et al.,8 included a density-adapted 3D radial 
projection reconstruction pulse sequence (TE/
TR = 0.2/120 ms, 17,000 projections and 369 samples 
per projection, readout time per spoke = 20 ms, flip 
angle = 87°, nominal voxel size = 3.6 × 3.6 × 3.6 mm3, 
acquisition time ≈ 34 min). External references (two 
tubes filled with 2% agarose doped with a sodium 
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concentration of 50 mmol/L) were placed on either 
side of the subject’s head, in the field of view, for 
absolute sodium quantification.
The full acquisition time was approximately 1½ hours. 
After 23Na-MRI acquisition performed with the double 
tuned 23Na-1H volume head coil, patient was repositioned 
in the scanner to perform the 1H-MRI and 1H-MRSI pro-
tocol using the 32-channel receiver 1H head coil.
Data processing
Metabolic maps (Figure 2) obtained for each subject 
were post-processed and combined (AC-PC + AC-PC 
15°) using the Metabolite Imaging and Data Analyses 
System (MIDAS, Trac, MRIR, Miami) software and 
SPM12 (Welcome Trust Centre for Neuroimaging at 
University College, London) following the procedure 
described in Donadieu et al.20
Radial 23Na acquisitions were reconstructed via an in-
house MATLAB (R 2011b, MathWorks Inc., Natick, 
MA) procedure.21 Quantitative 3D 23Na concentration 
maps (Figure 2) were obtained using the procedure 
described in Zaaraoui et al.8 with SPM12.
WM T2-lesion masks were delineated on T2-weighted 
images by the same expert (S.G., with 4 years of expe-
rience) using a semi-automated method (interactive 
thresholding technique written on the Interactive Data 
Language platform, version 7.0; Exelis Visual 
Information Solutions, Inc.).10
All maps were spatially normalized in the same MNI 
space (SPM12). Segmentation of MPRAGE was per-
formed using SPM12 and GM, WM, cerebrospinal 
fluid (CSF) density probability maps were spatially 
normalized in the MNI space.
For each patient, the transformation matrix obtained 
during the MNI spatial normalization of the T2-
weighted images was applied to its corresponding 
WM T2 lesion mask to obtain the individual normal-
ized WM T2 lesion mask. Then, this mask was used as 
region of interest (ROI) to extract metabolic and ionic 
values from the normalized maps of the given patient 
and all controls. The procedure was redone for each 
patient to account for potential metabolic and ionic 
regional normal physiological variations in controls 
among the different spatial distributions matching the 
T2 WM lesions in patients.
Figure 1. Examples of quality of spectra obtained over the whole brain using the 3D-1H-EPSI sequence (male, 31 years 
old). The horizontal scale is shown in ppm.
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To characterize metabolic and ionic profiles of MS 
patients within GM, spatially normalized ionic and 
metabolic maps were masked by the normalized GM 
probability density maps thresholded at 75% before 
extracting parameters from 90 GM ROIs (note that 
those including less than 20 voxels were not used) of 
the Automated Anatomical Labelling 2 (AAL 2) 
atlas.
To characterize metabolic and ionic profiles within 
the normal-appearing WM, all spatially normalized 
ionic and metabolic maps were masked by the nor-
malized WM probability density maps thresholded at 
75% (after subtraction of the normalized WM T2 
lesion masks) before extraction of parameters from 
the 12 WM regions corresponding to different lobes 
(frontal, parietal, limbic, temporal and occipital) 
(WFU pick atlas toolbox, SPM12).
These procedures were automated through a pipeline 
written in MATLAB (Figure 3). All ionic and meta-
bolic values for each ROI were normalized using 
Z-scores based on the mean and standard deviation 
values obtained for the control group from the corre-
sponding ROIs
For each ROI: -scoreZ
X
=
−µ
σ
where X = value of [23Na], NAA, Cho, tCr, Glx, m-Ins 
for each subject; µ = mean value of [23Na], NAA, Cho, 
tCr, Glx, m-Ins for the control group; and σ = standard 
deviation value of [23Na], NAA, Cho, tCr, Glx, m-Ins 
for the control group.
For each parameter and each subject, the Z-scores 
were averaged across regions belonging to the same 
compartment to obtain Z-scores of GM, NAWM and 
WM T2 lesions.
The Z-score allows us to calculate the standard devia-
tion of a score compared to a control group and ena-
bles us to compare two scores that are from different 
normal distributions. Z-scores of ROIs belonging to 
each compartment (GM, NAWM) were averaged for 
Figure 2. Examples of maps obtained from one subject (female, 29 years old) projected on MNI T1 template: (a) sodium, 
(b) N-acetyl aspartate, (c) glutamate–glutamine, (d) total creatine, (e) choline and (f) myo-inositol.
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each subject and each metabolic/ionic map. Note that 
for the computation of Z-scores corresponding to WM 
T2 lesions, for each patient, control data values were 
obtained from ROIs defined as the individual spa-
tially normalized WM T2 lesion mask built for each 
patient and applied to the spatially normalized maps 
of all controls to extract mean and SD.
Clinical score assessment
Clinical status was assessed on the day of the MR 
examination using the Kurtzke Expanded Disability 
Status Scale (EDSS) and the Multiple Sclerosis 
Functional Composite (MSFC) score, which is com-
posed of the paced auditory serial additional test 
(PASAT), the timed 25-foot walk (TFW) and the 
9-hole peg test (9HPT).
Statistical analyses
Statistical analyses were performed with JMP 9 
software (Version 13, September 2016, SAS insti-
tute). Wilcoxon rank tests were used to compare 
ionic and metabolic parameters observed between 
RRMS and controls within each independent com-
partment (GM, NAWM and WM T2 lesions). The 
multiple comparison procedure considered the three 
compartments as independent leading to a 
Bonferroni correction factor of 6 (pcorr < 0.008).
To test the relationships between TSC and metabolite 
levels in RRMS patients, a stepwise regression model 
(forward) was performed for each compartment with 
Z-TSC as the dependent variable and Z-NAA, Z-Glx, Z-tCr, 
Z-Cho, Z-mIns, GM%, WM% and CSF% as factors.
Correlations between average Z-scores 23Na and 
Z-scores of metabolic parameters for each independ-
ent compartment were assessed using Spearman rank 
tests (p < 0.05, corrected by Bonferroni procedure 
with a Bonferroni factor of 5 pcorr < 0.01).
Finally, stepwise regression models (forward) were 
built to explain MSFC and EDSS with Z-NAA, Z-Glx, 
Z-tCr, Z-Cho, Z-mIns, GM%, WM%, CSF% and T2 lesion 
load as factors.
Results
On the day of the MR study, all patients were sta-
ble, exhibiting no gadolinium-enhancing lesions or 
relapses. In all, 81% of patients (17 out of 21) were 
Figure 3. Post-processing pipeline including normalization in the MNI EPI spatial space, 23Na and metabolites values 
extraction for each ROI of GM, WM and T2 lesions and Z-scores computation.
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under immunosuppressive or immunomodulatory 
disease-modified treatments. Median EDSS was 1, 
ranging from 0 to 4, median MSFC was −0.28, 
ranging from −5.82 to 1.58, and median disease 
duration was 5.6 years, ranging from 2.8 to 
34.5 years.
Ionic and metabolic profiles of RRMS patients
All results are summarized in the radar plots shown in 
Figure 4. In GM, when compared to controls, RRMS 
patients showed significant increases in TSC 
(p = 0.0061), with decreases in Cho (p = 0.0070) and 
Glx (p = 0.0011) and a trend of decreased NAA 
(p = 0.0610) (Wilcoxon rank test).
In NAWM, RRMS had significant increases in TSC 
(p = 0.0002) and m-Ins (p = 0.0053), with decreases in 
NAA (p = 0.0232) and Glx (p = 0.0167).
Within T2 WM lesions, RRMS showed significant 
increases in TSC (p < 0.0001) and m-Ins (p = 0.0053) 
and decreases in NAA (p < 0.0001).
Association between total sodium accumulations 
and metabolite concentrations within the different 
brain compartments
Pairwise tests (p < 0.005) show significant correla-
tions between 23Na Z-score and metabolites Z-score in 
the three compartments, especially between TSC and 
NAA. All the results are summarized in Supplemental 
Table 1.
For the GM compartment of RRMS patients, the 
stepwise regression model showed significant asso-
ciation between increases in TSC and decreases in 
NAA (β = −0.831; p < 0.0032) (adjusted R2 = 0.341, 
p < 0.0032).
Figure 4. Radar plot of mean Z-scores of sodium and metabolites observed in RRMS patients within the three 
compartments (GM, NAWM, T2 lesions). The asterisks indicate significant differences between patients and healthy 
controls (Wilcoxon test p < 0.05 corrected by the Bonferroni procedure). Dotted lines represent the mean Z-scores of 
healthy controls (Z-score = 0).
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In NAWM, the stepwise regression model showed a 
significant association between increases in TSC and 
decreases in NAA (β = −1.069; p < 0.0047) (adjusted 
R2 = 0.346, p = 0.0085).
Within WM T2 lesions, increase in TSC was associ-
ated with decrease in NAA (β = −1.261; p < 0.0001) 
and smaller decrease in m-Ins (β = −2.693; p = 0.0030) 
and increase in tCr (β = 2.822; p = 0.0017) (adjusted 
R2 =  0.574, p = 0.0005).
Correlation between clinical scores (EDSS, 
MSFC) and ionic or metabolic profiles
The stepwise regression model including all ionic and 
metabolic parameters and T2 lesion load retained only 
the association between EDSS and decreased GM Glx 
(β = −1.288, p = 0.0288) (adjusted R2 =  0.187, 
p = 0.0288).
Concurrently, MSFC was positively associated with 
GM Glx (β = 1.066, p = 0.0123) (adjusted R2 = 0.249, 
p = 0.0123).
Discussion
We provide here, for the first time, the metabolic 
counterparts of total sodium accumulations observed 
in brain compartments of RRMS patients. A major 
challenge reached by this study is the assessment of 
whole brain ionic and metabolic samplings in vivo 
using 23Na-MRI and fast 3D 1H-EPSI acquisitions 
during the same clinical examination. In agreement 
with previous studies, we first confirmed the presence 
of abnormal cerebral increases of TSC in MS 
patients,7,8,11 concomitant to decreased NAA within 
NAWM and T2 WM lesions (trend for GM), decreased 
Glx within GM and NAWM, decreased Cho within 
GM, and increased m-Ins within NAWM and WM T2 
lesions.20,22,23
NAA decrease has been widely reported in RRMS 
patients within different brain regions including T2 
lesions,24 NAWM,24 deep GM25 and cortical GM.20 
This decrease has been interpreted as both neuro-
axonal damage and loss based on post-mortem histo-
logical studies.18 The main result of this study was that 
the stepwise regression models accounting for tissue 
content mainly showed a negative correlation between 
total sodium accumulations and NAA levels. This is 
the first in vivo evidence that chronic brain increases 
of TSC are significantly related to mitochondrial neu-
ronal dysfunction in all compartments. Previous in 
situ studies have proposed that sodium accumulations 
are related to neurodegenerative processes in MS.3,4 
Neuronal mitochondrial energy failure coupled with 
demyelination leads to Na+/K+ ATPase pump dys-
function and reorganization of sodium channels along 
axons.4,26 Such dysfunction drives 23Na accumulation 
inside the neurons and reverses Na+/Ca2+ exchange 
activity. Ca2+ inflow stimulates a large array of Ca2+-
dependent enzymes like calpains, phospholipases or 
nitric oxide synthases, driving structural and func-
tional axonal injury.3,4
While increase in glutamate has been observed in 
acute and active WM lesions reflecting excitotoxic-
ity27 and is considered a promising biomarker for MS 
disease progression,28 the present decrease in Glx 
may reflect neuro-astrocytic metabolic dysfunctions 
within GM and NAWM.16 Interestingly, the largest 
ionic/metabolic impact on global functional scores 
(EDSS and MSFC) was related to the GM Glx levels, 
in accordance with the fact that neuro-glial interac-
tions occur preferentially in GM nearby synapses.29 
Whenever not surviving the stepwise regression 
model, paired correlations showed significant nega-
tive association between TSC and GM Glx levels, in 
line with the major role of sodium in neuro-glial 
interactions.30 Study on experimental autoimmune 
encephalomyelitis (EAE) animal model highlights 
the major role of cytokines and glutamate on synaptic 
transmission deregulation and thereby on neurode-
generation, the main substrate of irreversible disabil-
ities in MS.31
Decrease of Cho in GM appear to conflict with previ-
ous literature reporting increase of Cho in T2 lesions,32 
NAWM and GM.17 This apparent discrepancy with 
the majority of MRS works related to MS may be 
explained by the different metabolites included in the 
Cho peak having opposite behaviour during demyeli-
nation and demyelination-inflammation processes. 
Decreased Cho has been reported in inflammatory 
and non-inflammatory Cuprizone models of MS and 
interpreted as a decrease in glycerophosphatidylcho-
line (GPC).33 Considering the whole group of patients 
relative to controls, the significant decrease of Cho 
levels could be interpreted as a large decrease of GPC 
reflecting mitochondrial dysfunction.33 This lack of 
Cho increase can be linked to the random distribution 
of Cho increase undetectable in this group analysis or 
with decrease of GPC signal reflecting mitochondrial 
dysfunction.33
Increase of m-Ins in NAWM and T2 lesions are also 
widely reported in the literature.34 Indeed, m-Ins is 
involved in brain inflammation through glial activa-
tion (mostly astrocytes)34 especially in the WM 
T2 lesions during the early stages of MS (CIS, RR < 5 
Multiple Sclerosis Journal 25(1)
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years),22 spreading to NAWM after 5 years.34 
Increased m-Ins in NAWM and especially in WM T2 
lesions may reflect enhanced glial processes (scars 
and/or activation).
This exploratory study has some limitations. First, the 
sample size (n = 21 patients) is relatively limited. 
Second, both imaging modalities suffer from rela-
tively low signal to noise, which impacts spatial reso-
lution and increases partial volume effects. We tried 
to minimize this effect by first applying WM and GM 
mask thresholds of 75% on 23Na and 1H-MRSI data. 
In addition to the masking procedure, we have 
included in the regression analyses the tissue content 
of ROIs characterized by WM%, GM%, CSF% and 
by removing ROIs composed by less than 20 voxels 
after masking. We proposed a clinically compatible 
MR protocol that provided acquisition of whole brain 
23Na-MRI and 1H-MRSI, enabling metabolic and 
sodium brain concentrations to be measured within 
the same subjects in vivo and non-invasively. Even if 
the volumic images were easily spatially normalized 
in the common MNI template, these multimodal 
(multicontrast) images may suffer from registration 
errors that may impact the correlation measurements. 
Finally, even if metabolite maps were not expressed 
in absolute concentrations, metabolite signals were 
normalized by the interleaved water signal acquired 
during the same acquisition,19 a procedure shown to 
be adequate even for multi-centre studies35 but not 
accounting for potential changes in T1 relaxation rates 
of water and metabolites.
In conclusion, a clinically compatible MR protocol 
was developed that provided acquisition of whole 
brain 23Na-MRI and 1H-MRSI, enabling metabolic 
and sodium brain concentrations to be measured 
within the same subjects in vivo and non-invasively. 
This study showed for the first time that the metabolic 
counterpart of total sodium accumulations observed 
in MS patients was related to neuronal mitochondrial 
dysfunction.
Future work will aim at deciphering the association 
between intracellular 23Na concentrations and meta-
bolic profiles using more specific methods of brain 
compartmentalization at ultra-high field (7T) such as 
TQF13 or multi-TE sequences14 allowing the separa-
tion of the contribution of restricted and free pools of 
sodium to the 23Na-MRI signal.
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